Pursuit or discontinuation of anti-PD1 after 2 years of treatment in long-term responder patients with non-small cell lung cancer

BACKGROUND: The optimal duration of immune checkpoint inhibitor (ICI) treatment for patients with advanced non-small cell lung cancer (NSCLC) remains to be determined. Treatment durations in cornerstone phase 3 clinical trials vary between a fixed 2-year duration and pursuit until disease progressio...

Descripción completa

Detalles Bibliográficos
Autores principales: Ardin, Camille, Humez, Sarah, Leroy, Vincent, Ampere, Alexandre, Bordier, Soraya, Escande, Fabienne, Turlotte, Amélie, Stoven, Luc, Nunes, David, Cortot, Alexis, Gauvain, Clément
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501064/
https://www.ncbi.nlm.nih.gov/pubmed/37720494
http://dx.doi.org/10.1177/17588359231195600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501064/
https://www.ncbi.nlm.nih.gov/pubmed/37720494
http://dx.doi.org/10.1177/17588359231195600

Ejemplares similares